Latest Breaking News On - Bio cardiorenal - Page 2 : comparemela.com

BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U S Food and Drug

- NDA submission is based on positive results from ATTRibute-CM Phase 3 study, including a highly statistically significant result, demonstrated by a Win Ratio of 1.8 (p<0.0001), on the primary

Jonathan foxBio cardiorenalVikram baliExchange commissionSecurities exchangeBridgebio pharma incCompany phaseWin ratioBio pharmaChief medical officerSecurities actSecurities exchange actExchange actRisk factorsAnnual reportBio media contact

BridgeBio Pharma (BBIO) Announces Submission of NDA to FDA for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma (BBIO) Announces Submission of NDA to FDA for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jonathan foxBio cardiorenalCompany phaseBridgebio pharma incBridgebio pharmaChief medical officerWin ratio

BridgeBio Pharma Announces Submission of New Drug

BridgeBio Pharma Announces Submission of New Drug
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Jonathan foxBio cardiorenalVikram baliCompany phaseBridgebio pharma incExchange commissionSecurities exchangeWin ratioBio pharmaChief medical officerAbout bridgebioSecurities actSecurities exchange actExchange actRisk factorsAnnual report

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

The company intends to file a New Drug Application (NDA) for acoramidis with the U.S. Food and Drug Administration (FDA) by end of 2023

United statesJonathan foxBio cardiorenalUs social security administrationEuropean society of cardiology congressSteering committeeUs department of healthUniversity of south carolinaBridgebio pharma incAmerican heart associationHuman servicesBridgebio pharmaScientific sessionsEuropean societyCardiology congressDaniel judge

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBio cardiorenalVikram baliJonathan foxUniversity of south carolinaUs social security administrationAmerican heart associationDrug administrationExchange commissionSteering committeeBio pharma incEuropean society of cardiology congressHuman servicesSecurities exchangeBridgebio pharma incUs department of health